[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100656848":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":11,"armGroups":19,"interventions":46,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":52,"collaborators":11,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":11,"eligibilityCriteria":59,"healthyVolunteers":56,"sex":60,"minAge":61,"maxAge":11,"enrollmentInfo":62,"targetDuration":11,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":11,"overallStatus":71,"whyStopped":11,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":11},{"fullName":5,"class":6},"Shanghai Zhongshan Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Major Pathological Response Rate",null,"At surgery, approximately 10-12 weeks after treatment initiation.",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"NON_RANDOMIZED","PARALLEL","TREATMENT",{"masking":18,"maskingDescription":11,"whoMasked":11},"NONE",[20,26,30,34,38,42],{"label":21,"type":22,"description":23,"interventionNames":24},"EGFR Exon 20 Insertion Cohort","EXPERIMENTAL","Sunvozertinib",[25],"Procedure: Surgical Resection",{"label":27,"type":22,"description":28,"interventionNames":29},"ALK Fusion Cohort","Alectinib",[25],{"label":31,"type":22,"description":32,"interventionNames":33},"ROS1 Fusion Cohort","Entrectinib",[25],{"label":35,"type":22,"description":36,"interventionNames":37},"MET Exon 14 Skipping Cohort","Tepotinib",[25],{"label":39,"type":22,"description":40,"interventionNames":41},"RET Fusion Cohort","Selpercatinib",[25],{"label":43,"type":22,"description":44,"interventionNames":45},"KRAS G12C Mutation Cohort","Fulzerasib",[25],[47],{"type":48,"name":49,"description":50,"armGroupLabels":51,"otherNames":11},"PROCEDURE","Surgical Resection","Curative-intent resection following targeted therapy in participants considered suitable for surgery.",[27,21,43,35,39,31],{"type":53,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100656848","phase-2-perioperative-targeted-therapy-in-resectable-or-potentially-resectable-stage-iii-non-small-cell-lung-cancer-with-rare-driver-mutations-100656848",false,"NCT07829744","Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations","Inclusion Criteria:\n\n* Age ≥18 years.\n* Histologically or cytologically confirmed stage III NSCLC (AJCC 8th edition), considered resectable or potentially resectable.\n* Documented EGFR exon 20 insertion, ALK fusion, ROS1 fusion, MET exon 14 skipping alteration, RET fusion, or KRAS G12C mutation.\n* At least one measurable lesion per RECIST 1.1 and ECOG performance status 0-1.\n* Adequate cardiopulmonary and major organ function for surgery.\n* Written informed consent and willingness to comply with study procedures, sample collection, and follow-up.\n\nExclusion Criteria:\n\n* Stage III NSCLC considered unresectable by surgical assessment.\n* Lung cancer treatment within the previous 2 years, or prior lung cancer with a remission duration of less than 2 years.\n* Another malignancy within the previous 5 years.\n* Major surgery within 28 days before the first study dose.\n* Any contraindication to the assigned targeted therapy.\n* Inability or unwillingness to provide informed consent or comply with study requirements.","ALL","18 Years",{"count":63,"type":64},190,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","This study evaluates the effectiveness and safety of targeted therapy given before and after surgery in patients with resectable or potentially resectable stage III non-small cell lung cancer with selected genetic alterations. Treatment is assigned according to tumor genetic findings.",[70],"Lung Cancer (NSCLC)","NOT_YET_RECRUITING","2026-09-15",{"date":74,"type":75},"2026-09-21","ACTUAL",{"date":77,"type":64},"2026-09-20",{"date":79,"type":64},"2030-06-30",{"name":5,"class":6}]